SEHK:2600
SEHK:2600Metals and Mining

Is Aluminum Corporation of China (SEHK:2600) Still Attractive After Its Recent Share Price Surge

If you are wondering whether Aluminum Corporation of China at HK$13.37 is still good value after a strong run, this article walks through what the current price might be implying about the company. The stock has posted returns of 9.9% over the last 7 days, 24.1% over the last 30 days, 5.8% year to date, 208.1% over 1 year and 281.1% over 3 years, with a very large gain over 5 years of 452.0%. Recent interest in Aluminum Corporation of China has been closely watched by investors, who are...
SEHK:2490
SEHK:2490Shipping

3 Promising Asian Penny Stocks With Market Caps Under US$400M

As we enter 2026, Asian markets are reflecting a mix of cautious optimism and strategic positioning, with investors closely watching economic indicators and policy shifts. Amidst this backdrop, penny stocks—often representing smaller or newer companies—continue to capture attention for their potential to offer significant growth opportunities at lower price points. While the term "penny stock" might seem outdated, these investments can still present valuable prospects when backed by strong...
SEHK:981
SEHK:981Semiconductor

Is It Too Late To Consider Semiconductor Manufacturing International (SEHK:981) After 138% Annual Surge?

If you are wondering whether Semiconductor Manufacturing International is attractively priced right now, you are not alone. This article will walk through what the current share price may imply about its value. The stock last closed at HK$74.95, with returns of 4.9% over 7 days, 8.9% over 30 days, a 0.2% decline year to date, and gains of 138.3% over 1 year, 337.3% over 3 years and 166.3% over 5 years. These moves sit against a backdrop of ongoing attention on global chip supply, sector...
SEHK:9966
SEHK:9966Biotechs

Alphamab Oncology (SEHK:9966) Valuation Check After JSKN033 Phase II Trial Clearance In China

Regulatory milestone and why it matters for Alphamab Oncology Alphamab Oncology (SEHK:9966) has drawn attention after regulators in China accepted its investigational new drug application for a phase II trial of JSKN033 in first line advanced cervical cancer. The open label, multicenter study will test a high concentration subcutaneous co formulation. It combines a HER2 bispecific antibody drug conjugate with a PD L1 inhibitor, alongside platinum based chemotherapy with or without...
SEHK:1211
SEHK:1211Auto

Assessing BYD (SEHK:1211) Valuation As It Overtakes Tesla In Battery Electric Vehicle Sales

BYD (SEHK:1211) has just reported unaudited December 2025 production and sales figures, alongside confirmation that it surpassed Tesla as the largest seller of battery electric vehicles, putting fresh attention on how these volumes translate into margins. See our latest analysis for BYD. The latest operating data and EV leadership headlines come against a weaker share price backdrop, with a 90 day share price return decline of 12.52% and a 1 year total shareholder return of 12.23%. This...